LOGIN  |  REGISTER
Amneal Pharmaceuticals

Agilent Technologies to Announce First-Quarter Fiscal Year 2023 Financial Results Feb. 28

January 30, 2023 | Last Trade: US$118.69 0.39 0.33

SANTA CLARA, Calif. / Jan 30, 2023 / Business Wire / Agilent Technologies Inc. (NYSE: A) will release financial results for the first quarter of fiscal year 2023 after the stock market closes on Tuesday, Feb. 28. The company will host a live webcast of its earnings conference call in listen-only mode on the same day. Below are details for the webcast:

Date: Tuesday, Feb. 28, 2023.

Time: 1:30 p.m. Pacific time.

How to Join: Access the webcast link from the Events section of Agilent’s investor relations website. A replay of the call will be available for 90 days after the event.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in the life sciences, diagnostics, and applied chemical markets, delivering insight and innovation that advance the quality of life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.

Recursion

Stock Quote

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page